Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058415 | 0.94 | GPR119 (0.47) | GPR119DPP4DPP7ALDH1A1NPSR1 | |
| SCHEMBL610227 | 0.93 | GPR119 (0.45) | GPR119DPP4ALDH1A1RAB9A | |
| SCHEMBL10058417 | 0.92 | GPR119 (0.46) | GPR119DPP4DPP7 | |
| SCHEMBL10058419 | 0.88 | GPR119 (0.39) | GPR119DPP4DPP7 | |
| SCHEMBL609291 | 0.88 | GPR119 (0.45) | GPR119ALDH1A1RAB9A | |
| SCHEMBL10058411 | 0.87 | GPR119 (0.44) | GPR119MC4RALDH1A1NPSR1 | |
| SCHEMBL10058408 | 0.86 | GPR119 (0.48) | GPR119DPP4DPP7ALDH1A1NPSR1 | |
| SCHEMBL609212 | 0.86 | GPR119 (0.44) | GPR119DPP4ALDH1A1NPSR1RAB9A | |
| SCHEMBL10058406 | 0.84 | GPR119 (0.47) | GPR119ALDH1A1NPSR1 | |
| SCHEMBL611803 | 0.83 | GPR119 (0.43) | GPR119DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885DPP4 217/4885DPP7 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.